Abstract:Various heteroaryl and bicyclo-aliphatic analogues of zwitterionic biaryl P2Y14 receptor (P2Y14R) antagonists were synthesized, and affinity was measured in P2Y14R-expressing Chinese hamster ovary cells by flow cytometry. Given this series' low water solubility, various polyethylene glycol derivatives of the distally binding piperidin-4-yl moiety of moderate affinity were synthesized. Rotation of previously identified 1,2,3-triazole attached to the central m-benzoic acid core (25) provided moderate affinity but not indole and benzimidazole substitution of the aryl-triazole. The corresponding P2Y14R region is predicted by homology modeling as a deep, sterically limited hydrophobic pocket, with the outward pointing piperidine moiety being the most flexible. Bicyclic-substituted piperidine ring derivatives of naphthalene antagonist 1, e.g., quinuclidine 17 (MRS4608, IC50 ≈ 20 nM at hP2Y14R/mP2Y14R), or of triazole 2, preserved affinity. Potent antagonists 1, 7a, 17, and 23 (10 mg/kg) protected in an ovalbumin/Aspergillus mouse asthma model, and PEG conjugate 12 reduced chronic pain. Thus, we expanded P2Y14R antagonist structure–activity relationship, introducing diverse physical–chemical properties.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00745?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00745</a>.Synthesis of additional compounds (4-bromophenyl intermediates and carboxylate substitutions on the central phenyl ring of 2); off-target binding inhibition curves; pharmacological data; molecular modeling data, including docking poses of selected compounds, number of contacts between the receptor residues and the ligand in each MD replicate, RMSD and ligand–receptor interaction pattern during MD replicate 3, RMSD and ligand-receptor interaction pattern during MD replicate 4, and analysis of MD replicates; predicted pharmacokinetic parameters; predicted log D and log S; and methods to measure solubility and lipohilicity (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00745/suppl_file/jm0c00745_si_001.pdf">PDF</a>)NMR and mass spectra of final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00745/suppl_file/jm0c00745_si_006.pdf">PDF</a>)3D coordinates of hP2Y14R in complex with 17, obtained through molecular docking (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00745/suppl_file/jm0c00745_si_002.pdb">PDB</a>)MD trajectory (replicate 3) of the complex between compound 17 and hP2Y14R, after alignment of the receptor Cα atoms to the initial frame (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00745/suppl_file/jm0c00745_si_003.mp4">MP4</a>)MD trajectory (replicate 4) of the complex between compound 17 and hP2Y14R, after alignment of the receptor Cα atoms to the initial frame (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00745/suppl_file/jm0c00745_si_004.mp4">MP4</a>)Molecular formula strings of P2Y14R antagonists (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00745/suppl_file/jm0c00745_si_005.pdf">PDF</a>)This article has not yet been cited by other publications.

N-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides As A2A Receptor Antagonists with Improved Drug Like Properties and in Vivo Efficacy.

Design, Synthesis, And Sar Studies Of Heteroarylpyrimidines And Heteroaryltriazines As Cb2r Ligands

Novel Quinazoline Derivatives as Highly Effective A2A Adenosine Receptor Antagonists

Synthesis of Alkyne Derivatives of a Novel Triazolopyrazine As A2A Adenosine Receptor Antagonists.

2-Substituted (N)-Methanocarba A3 Adenosine Receptor Agonists: In Silico, In Vitro, and In Vivo Characterization

2-Aryladenine Derivatives as a Potent Scaffold for Adenosine Receptor Antagonists: The 6-Morpholino Derivatives

Synthesis and Pharmacological Characterization of 4-Substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates: Identification of New Potent and Selective Metabotropic Glutamate 2/3 Receptor Agonists.

2-Substituted -Methanocarba A3 Adenosine Receptor Agonists: In silico, in vitro and in vivo Characterization

Adenosine A 2A R/A 1 R Antagonists Enabling Additional H 3 R Antagonism for the Treatment of Parkinson’s Disease

Design, synthesis and biological evaluation of novel scaffold benzo[4,5]imidazo [1,2-a]pyrazin-1-amine: Towards adenosine A2A receptor (A2A AR) antagonist

Subtle Structural Changes Across the Boundary Between A2AR/A2BR Dual Antagonism and A2BR Antagonism: A Novel Class of 2-Aminopyrimidine-based Derivatives.

Discovery of Novel Benzo[4,5]imidazo[1,2- a ]pyrazin-1-amine-3-amide-one Derivatives as Anticancer Human A 2A Adenosine Receptor Antagonists

Exploration of Alternative Scaffolds for P2Y 14 Receptor Antagonists Containing a Biaryl Core

Chemistry And Pharmacological Characterization Of Novel Nitrogen Analogues Of Amop-H-Oh (Sazetidine-A, 6[5-(Azetidin-2-Ylmethoxy)Pyridin-3-Yl]Hex-5-Yn-L-Ol) As Alpha 4 Beta 2-Nicotinic Acetylcholine Receptor-Selective Partial Agonists

Structural Modification and Biological Evaluation of 2,8-Disubstituted Adenine and Its Nucleosides as A 2A Adenosine Receptor Antagonists: Exploring the Roles of Ribose at Adenosine Receptors

Subtle Structural Changes across the Boundary between A 2A R/A 2B R Dual Antagonism and A 2B R Antagonism: A Novel Class of 2-Aminopyrimidine-Based Derivatives

Design, Synthesis, and Bioevaluation of 2-Aminopteridin-7(8h)-one Derivatives As Novel Potent Adenosine A2A Receptor Antagonists for Cancer Immunotherapy

Discovery of N-Substituted Acetamide Derivatives as Promising P2Y 14 R Antagonists Using Molecular Hybridization Based on Crystallographic Overlay

Novel secondary pyridinyl amides: Synthesis, in vitro antiproliferative screenings, and molecular docking studies

Novel selective antagonist radioligands for the pharmacological study of A2B adenosine receptors